AtaiBeckley (ATAI) Other financing activities (2021 - 2026)
AtaiBeckley's (ATAI) quarterly Other financing activities came in at $821000.0 in Q1 2026, up 106.8% year-on-year from $397000.0 in Q1 2025, and up 106.8% quarter-over-quarter from $397000.0 in Q1 2025.
AtaiBeckley (ATAI) Other financing activities (2021 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 5 years of Other financing activities data on file, last reported at -$11.5 million in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities fell 3442.64% year-over-year to -$11.5 million; the trailing twelve-month figure through Sep 2025 stood at $535000.0 (up 604.72% YoY), and the FY2024 full-year result was $535000.0, up 435.0% from the prior year.
- Other financing activities rose to $821000.0 in Q1 2026 per ATAI's latest filing, from $397000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $821000.0 in Q1 2026 and bottomed at $397000.0 in Q1 2025.
- A 5-year average of $209214.3 and a median of $169000.0 in 2022 frame the typical range for Other financing activities.
- Peak annual rise in Other financing activities reached 3320.86% in 2025, while the deepest fall reached 3442.64% in 2025.
- Tracing ATAI's Other financing activities over 5 years: stood at -$534000.0 in 2021, then soared by 123.03% to $123000.0 in 2022, then sank by 186.18% to -$106000.0 in 2023, then soared by 604.72% to $535000.0 in 2024, then tumbled by 2258.69% to -$11.5 million in 2025.
- Business Quant data shows ATAI's Other financing activities at -$11.5 million in Q3 2025, $11.2 million in Q2 2025, and $397000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 821,000.00 |
| Mar 31, 2026 | 821,000.00 |
| Sep 30, 2025 | -11.55 Mn |
| Sep 30, 2025 | -11.55 Mn |
| Jun 30, 2025 | 11.15 Mn |
| Jun 30, 2025 | 11.15 Mn |
| Mar 31, 2025 | 397,000.00 |
| Mar 31, 2025 | 397,000.00 |
| Mar 31, 2025 | 397,000.00 |
| Mar 31, 2025 | 397,000.00 |
| Dec 31, 2024 | 535,000.00 |
| Dec 31, 2024 | 535,000.00 |
| Sep 30, 2024 | -326,000.00 |
| Sep 30, 2024 | -326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Dec 31, 2023 | -106,000.00 |
| Dec 31, 2023 | -106,000.00 |
| Mar 31, 2023 | 206,000.00 |
| Mar 31, 2023 | 206,000.00 |